| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Alex N Bullock | Q88223619 |
| Elizabeth J Brown | Q90261179 | ||
| P2093 | author name string | Eleanor Williams | |
| Jong Fu Wong | |||
| P2860 | cites work | Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva | Q90003989 |
| Challenges to curing primary brain tumours | Q91410839 | ||
| Long-term cognitive dysfunction after radiation therapy for primary brain tumors | Q91536079 | ||
| NHS and Vertex remain deadlocked over price of cystic fibrosis drug | Q92234979 | ||
| Cancer genome landscapes | Q22242276 | ||
| Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity | Q24317253 | ||
| A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva | Q24321505 | ||
| Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas | Q24339074 | ||
| BMP type I receptor inhibition reduces heterotopic [corrected] ossification | Q24611307 | ||
| Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva | Q24623325 | ||
| Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas | Q24629777 | ||
| Future Clinical Trials in DIPG: Bringing Epigenetics to the Clinic | Q26801858 | ||
| A new class of small molecule inhibitor of BMP signaling | Q27678000 | ||
| Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter | Q28208212 | ||
| Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma | Q28237518 | ||
| Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations | Q28237528 | ||
| Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2 | Q28283345 | ||
| Inherited Disease Genetics Improves the Identification of Cancer-Associated Genes | Q28550275 | ||
| Functionally defined therapeutic targets in diffuse intrinsic pontine glioma | Q28833173 | ||
| Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma | Q29616862 | ||
| Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism | Q29617479 | ||
| Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1 | Q30373949 | ||
| Cystic Fibrosis: Breakthrough Drugs at Break-the-Bank Prices | Q33457812 | ||
| The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma | Q33751426 | ||
| Pediatric high-grade glioma: biologically and clinically in need of new thinking | Q33777868 | ||
| ACVR1 mutations in DIPG: lessons learned from FOP. | Q34134675 | ||
| Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants | Q34313807 | ||
| Brainstem glioma: a review | Q34628180 | ||
| Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group | Q34722864 | ||
| Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma | Q34810691 | ||
| Both location and age predict survival in ependymoma: a SEER study. | Q34879188 | ||
| Choroid plexus tumours | Q34981284 | ||
| Late neurocognitive sequelae in survivors of brain tumours in childhood | Q35824972 | ||
| Neofunction of ACVR1 in fibrodysplasia ossificans progressiva | Q36394399 | ||
| Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. | Q36500381 | ||
| Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma | Q36561184 | ||
| Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma | Q36774588 | ||
| Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2. | Q36859278 | ||
| Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma | Q36936139 | ||
| Development of an ALK2-biased BMP type I receptor kinase inhibitor | Q37513815 | ||
| "Creating hope" and other incentives for drug development for children | Q37830230 | ||
| The long-term postsurgical prognosis of patients with pineoblastoma | Q37896017 | ||
| Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma | Q38259785 | ||
| Direct binding of Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic protein-specific transcriptional activation of Id1 gene | Q38294929 | ||
| Survival rates and prognostic predictors of high grade brain stem gliomas in childhood: a systematic review and meta-analysis. | Q38662239 | ||
| EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas | Q38713519 | ||
| Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. | Q38713523 | ||
| Downregulation of Id2 increases chemosensitivity of glioma | Q38899685 | ||
| ID2 promotes survival of glioblastoma cells during metabolic stress by regulating mitochondrial function. | Q38957890 | ||
| Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. | Q38978887 | ||
| Patterns of care and treatment outcomes of patients with Craniopharyngioma in the national cancer database. | Q39067273 | ||
| Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. | Q39173934 | ||
| Incidence and survival of children and young people with central nervous system embryonal tumours in the North of England, 1990-2013. | Q39790095 | ||
| Phosphorylation Regulates Id2 Degradation and Mediates the Proliferation of Neural Precursor Cells | Q41100382 | ||
| Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma | Q42375231 | ||
| Stereotactic biopsy of diffuse pontine lesions in children | Q48097339 | ||
| Pilocytic astrocytomas in children: prognostic factors--a retrospective study of 80 cases | Q48216031 | ||
| Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study | Q48285313 | ||
| Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma | Q48329991 | ||
| Expression and distribution of id helix-loop-helix proteins in human astrocytic tumors | Q48607876 | ||
| Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. | Q52718178 | ||
| ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. | Q54248766 | ||
| Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. | Q55456557 | ||
| Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept | Q58796966 | ||
| Ideation and implementation of an open science drug discovery business model - M4K Pharma | Q61451302 | ||
| Bis-Heteroaryl Pyrazoles: Identification of Orally Bioavailable Inhibitors of Activin Receptor-Like Kinase-2 (R206H) | Q62657038 | ||
| Brain tumor research in the United Kingdom: current perspective and future challenges. A strategy document from the NCRI Brain Tumor CSG | Q63386970 | ||
| ALK2 inhibitors display beneficial effects in preclinical models of mutant diffuse intrinsic pontine glioma | Q64059831 | ||
| ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis | Q64068988 | ||
| Bone morphogenetic proteins induce differentiation in astrocyte lineage cells | Q71670254 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P433 | issue | 5 | |
| P921 | main subject | brain tumor | Q233309 |
| antineoplastic | Q2853144 | ||
| P304 | page(s) | 1471-1479 | |
| P577 | publication date | 2019-10-01 | |
| 2019-10-31 | |||
| P1433 | published in | Biochemical Society Transactions | Q864226 |
| P1476 | title | Fostering open collaboration in drug development for paediatric brain tumours | |
| P478 | volume | 47 |
Search more.